NORYVA
Metabolism: a lead that began with an observation in humans.
10 mg
MOTS-c is a peptide whose blueprint does not come from the centre of the cell, but from its small power plants — a rare origin, and the reason it is studied apart. The work starts from an observation made in humans: effort raises the amount in the blood, and that level tracks measures of fat mass, lean mass and blood sugar.
The same reference, in pen format
The molecule is delivered in a sealed cartridge, inside a refillable anodised aluminium pen. It is not an accessory to add on: it is the other way of ordering the same reference, at its own price.
Has any study actually given it to people?
Not published yet. The first trial administering it is recruiting. What exists today are measurements made on the MOTS-c the body produces itself, during exercise programmes — an association, never the effect of a product. The difference matters, and we keep it written down.
A peptide that comes from the mitochondria rather than the cell nucleus: that origin alone is a reason to study it separately. What started the research is an observation made in humans — exercise raises the amount of it in the blood, and that level goes together with measurements of fat mass, lean mass and blood sugar. This work observes the MOTS-c the body makes itself; the first human trial that administers it is under way and has not published.
MOTS-c is a sixteen-amino-acid peptide encoded by mitochondrial DNA rather than by nuclear DNA. That origin is what makes it studied separately.
Mitochondria-derived peptides are a recent research subject: the question is whether they act as signals between the mitochondrion and the rest of the cell.
Proposed mechanism: involvement in cellular metabolic pathways. The peptide's physiological role is not established.
No clinical trial published to date. The available work is experimental.
In vitro and animal-model data, mainly metabolic.
Young research field, results to be confirmed. No marketing authorisation. A molecule's mitochondrial origin says nothing about its safety.
For laboratory research purposes only. Not for human consumption or therapeutic use.
This reference holds no marketing authorisation as a medicinal product.
No. This reference is not offered for sale: its commercial framework is not settled. No purchase button is shown until it is.
No. This reference holds no marketing authorisation as a medicinal product and is approved by no authority for human use. A publication or a clinical trial never amounts to approval.
The certificate of analysis is supplied with the batch delivered. No batch number or purity figure is published until the real certificate has been entered: we do not display illustrative values.
The storage requirement is not yet on file: the supplier data sheet has not reached us. We would rather say so than assume.
Compatibility is not confirmed for this reference. Until the manufacturer confirms it, we do not claim it.
Young research field, results to be confirmed. No marketing authorisation. A molecule's mitochondrial origin says nothing about its safety.
Conversion not published
How a graduation on the NORYVA pen maps to a volume depends on its mechanism. Its technical sheet is not on file: no conversion is shown until the manufacturer confirms it. We would rather write that than assume it.